Evidence map›Paper›PMID 38170154›Full record

ArticleOncoimmunology2024

Suyang Wang, Michelle Cheng, Chao-Cheng Chen, Chia-Yu Chang, Ya-Chea Tsai, Jr-Ming Yang, T C Wu, Chuan-Hsiang Huang, Chien-Fu Hung

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. AttenuatedFrontiers in immunology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Suyang WangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michelle ChengDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chao-Cheng ChenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chia-Yu ChangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ya-Chea TsaiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jr-Ming YangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
T C WuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chuan-Hsiang HuangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chien-Fu HungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of SalmonellaR21DE029910 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$450k
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccineR21CA234516 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$421k
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancerR21CA256020 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2021 to 2022
$417k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA237067NCI NIH HHS R21 CA234516NCI NIH HHS R21 CA256020NIDCR NIH HHS R21 DE029910
6 · The paper itself

Abstract

Bacteria-based cancer therapy employs various strategies to combat tumors, one of which is delivering tumor-associated antigen (TAA) to generate specific immunity. Here, we utilized a poly-arginine extended HPV E7 antigen (9RE7) for attachment on Salmonella SL7207 outer membrane to synthesize the bacterial vaccine Salmonella-9RE7 (Sal-9RE7), which yielded a significant improvement in the amount of antigen presentation compared to the previous lysine-extended antigen coating strategy. In TC-1 tumor mouse models, Sal-9RE7 monotherapy decreased tumor growth by inducing E7 antigen-specific immunity. In addition, pairing Sal-9RE7 with adjuvant Albumin-IFNβ (Alb-IFNβ), a protein cytokine fusion, the combination significantly increased the antitumor efficacy and enhanced immunogenicity in the tumor microenvironment (TME). Our study made a significant contribution to personalized bacterial immunotherapy via TAA delivery and demonstrated the advantage of combination therapy.

Indexed as

Interferon Type INeoplasmsAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesImmunotherapyMicePapillomavirus E7 ProteinsSalmonellaTumor MicroenvironmentAntigens, NeoplasmInterferon Type IPapillomavirus E7 ProteinsBacterial immunotherapyCD8+ T cellCell penetrating peptideCervical cancerSalmonellaTumor antigenType I inteferon

Identifiers

PMID38170154
PMCPMC10761047
OpenAlexW4390341635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.